IL18 and Sepsis: The results showed that AC-YVAD-CMK treatment significantly reduced the expression levels of Caspas-1, NLRP-1, IL-1β, and IL-18 compared with those of the CLP group, confirming that AC-YVAD-CMK could reduce pyroptosis and sepsis-induced acute kidney injury (Figure 4).